GSK plc (NYSE:GSK) Holdings Reduced by Peoples Bank KS

Peoples Bank KS lowered its position in GSK plc (NYSE:GSK) by 47.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,045 shares of the pharmaceutical company’s stock after selling 4,525 shares during the quarter. Peoples Bank KS’s holdings in GSK were worth $171,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Eastern Bank bought a new position in GSK in the 3rd quarter worth approximately $26,000. Sunbelt Securities Inc. grew its stake in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Concord Wealth Partners grew its stake in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the second quarter valued at $37,000. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the third quarter valued at about $42,000. Institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.4 %

GSK stock opened at $34.11 on Wednesday. The firm has a market cap of $70.69 billion, a PE ratio of 22.15, a P/E/G ratio of 1.52 and a beta of 0.63. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a 50 day simple moving average of $34.59 and a 200 day simple moving average of $38.30.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.61%. The ex-dividend date is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 98.70%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Sunday. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.